ALVOTECH

NASDAQ: ALVO (Alvotech)

最近更新时间: 4小时之前

5.22

0.16 (3.16%)

  • 1天 3.16%
  • 5天 -4.92%
  • 1月 -38.73%
  • 6月 -48.62%
  • 今年至今天 -60.33%
  • 1年 -58.04%
  • 5年 -53.35%
前收盘价格 5.06
收盘价格 5.12
成交量 204,863
平均成交量 (3个月) 500,557
市值 1,626,557,952
市盈率 (P/E TTM) 22.70
预期市盈率 (P/E Forward) 11.36
价格/销量 (P/S) 2.80
52周波幅
4.70 (-9%) — 13.70 (162%)
利润日期 12 Nov 2025
营业毛利率 16.42%
营业利益率 (TTM) 7.97%
稀释每股收益 (EPS TTM) 0.370
季度收入增长率 (YOY) 260.00%
季度盈利增长率 (YOY) -65.50%
流动比率 (MRQ) 1.73
营业现金流 (OCF TTM) -148.89 M
杠杆自由现金流 (LFCF TTM) -216.76 M
资产报酬率 (ROA TTM) 7.02%

市场趋势

短期 中期
行业 Drug Manufacturers - Specialty & Generic (US) 看涨 混合的
Drug Manufacturers - Specialty & Generic (全球的) 看涨 混合的
股票 Alvotech 看跌 看跌

AIStockmoo 评分

1.0
分析师共识 1.0
内部交易活动 NA
价格波动 3.0
技术平均移动指标 2.5
技术振荡指标 -2.5
平均 1.00

相关股票

股票 市值 DY P/E（TTM） P/B
ALVO 2 B - 22.70 -
LNTH 4 B - 21.62 3.14
KNSA 3 B - 89.53 5.72
BCRX 1 B - - 56.59
HROW 1 B - - 31.74
ETON 514 M - - 18.90

Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to treatments for various diseases.
部门 Healthcare
行业 Drug Manufacturers - Specialty & Generic
投资方式 Small Growth
内部持股比例 63.44%
机构持股比例 6.44%

所有权

姓名 日期 持有股份
Bracebridge Capital, Llc 30 Sep 2025 2,705,304
Oaktree Capital Management Lp 30 Sep 2025 1,563,676
Littlejohn & Co Llc 30 Sep 2025 1,318,534
Pointstate Capital Lp 30 Sep 2025 1,049,039
Farallon Capital Management Llc 30 Sep 2025 199,675
Lodbrok Capital Llp 30 Sep 2025 181,587
52周波幅
4.70 (-9%) — 13.70 (162%)
目标价格波幅
8.00 (53%) — 14.00 (168%)
高 14.00 (Morgan Stanley, 168.20%) 购买
中 10.00 (91.57%)
低 8.00 (Deutsche Bank, 53.26%) 保留
平均值 10.67 (104.41%)
总计 2 购买, 1 保留
平均价格@调整类型 6.15
公司 日期 目标价格 调整类型 价格@调整类型
UBS 18 Nov 2025 10.00 (91.57%) 购买 5.11
Deutsche Bank 04 Nov 2025 8.00 (53.26%) 保留 4.83
23 Sep 2025 14.00 (168.20%) 购买 8.70
Morgan Stanley 14 Oct 2025 14.00 (168.20%) 购买 8.50

该时间范围内无数据。

  • 3M
日期 类型 细节
20 Nov 2025 公告 Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab)
20 Nov 2025 公告 Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab)
12 Nov 2025 公告 Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update
12 Nov 2025 公告 Alvotech Reports Results for the First Nine Months of 2025 and Provides a Business Update
10 Nov 2025 公告 UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® (aflibercept)         
10 Nov 2025 公告 UK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® (aflibercept)
06 Nov 2025 公告 Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA
06 Nov 2025 公告 Alvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRA
04 Nov 2025 公告 Alvotech Announces Webcast on November 13, 2025 to Report Financial Results for the First Nine Months of 2025 and Provide a Business Update
04 Nov 2025 公告 Alvotech Announces Webcast on November 13, 2025 to Report Financial Results for the First Nine Months of 2025 and Provide a Business Update
02 Nov 2025 公告 Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05
02 Nov 2025 公告 Alvotech Provides Update on the Status of U.S. Biologics License Application for AVT05
22 Oct 2025 公告 Alvotech Announces Changes in Global Business Development and Commercial Operations Team
22 Oct 2025 公告 Alvotech Announces Changes in Global Business Development and Commercial Operations Team
06 Oct 2025 公告 Kashiv Biosciences Announces Submission of Biologics License Application to U.S. FDA and Acceptance of Market Authorization Application by European Medicines Agency for ADL-018, a Proposed Biosimilar to XOLAIR® (omalizumab)
06 Oct 2025 公告 European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency
06 Oct 2025 公告 European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency
22 Sep 2025 公告 European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech’s Proposed Biosimilar to Prolia® and Xgeva®
22 Sep 2025 公告 European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech’s Proposed Biosimilar to Prolia® and Xgeva®
22 Sep 2025 公告 European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech’s Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner
22 Sep 2025 公告 European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech’s Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner
19 Sep 2025 公告 Alvotech Announces Marketing Approval in Japan of Three New Biosimilars
19 Sep 2025 公告 Alvotech Announces Marketing Approval in Japan of Three New Biosimilars
04 Sep 2025 公告 Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York
04 Sep 2025 公告 Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York
21 Aug 2025 公告 Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®
21 Aug 2025 公告 Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®
显示更多

支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明：以上内容仅供参考，并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2025 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票